Open Label Study of BAY1082439 in Patients With Advanced Cancer
The purpose of this study is to determine the safety, tolerability and the pharmacokinetics of BAY1082439
Neoplasms
DRUG: BAY1082439
Number of participants with adverse events as a measure of safety and tolerability, Up to 2 years|Maximum tolerated dose of BAY1082439, Up to 1 year|Maximum observed plasma concentration (Cmax) of BAY1082439 after a single dose, Serial PK samples will be selected during cycle 1 day 1 (pre-dose and 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours post-dose) and sparse samples during the rest of the cycle as well as in cycle 2|Time to Cmax (tmax) of BAY1082439 after a single dose, Serial PK samples will be selected during cycle 1 day 1 (pre-dose and 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours post-dose) and sparse samples during the rest of the cycle as well as in cycle 2|Area under the plasma concentration-time curve (AUC[0-t]) of BAY1082439 after a single dose, Serial PK samples will be selected during cycle 1 day 1 (pre-dose and 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours post-dose) and sparse samples during the rest of the cycle as well as in cycle 2
Area under the concentration-time curve over the dosing interval (AUC[0-tau]), PK parameters following single and repeat-dose administration in cycle 1|Maximum observed concentration (Cmax), PK parameters following single and repeat-dose administration in cycle 1|Time of occurrence of Cmax (tmax), PK parameters following single and repeat-dose administration in cycle 1|Terminal phase half-life (t1/2), PK parameters following single and repeat-dose administration in cycle 1|Tumor response based on Response Evaluation Criteria in Solid Tumors, Version 1.1, Up to 2 years
The purpose of this study is to determine the safety, tolerability and the pharmacokinetics of BAY1082439